Praxis Pharmaceutical
An innovative company specialized in the advanced treatment of chronic wounds

ABOUT US

Praxis Pharmaceutical is a company with a long-standing record in the pharmaceutical industry, specialising in the advanced treatment of chronic wounds.

As part of its international strategy, Praxis dedicates all its expertise and experience to marketing innovative medicines and medical devices within its area of expertise.

Focused on patient well-being

Mission icon

Mission

Praxis Pharmaceutical’s mission is to deliver effective solutions for complex wound-healing. For this purpose, we provide healthcare professionals with innovative drugs and medical devices that extend the therapeutic arsenal in order to improve patient treatment.

Vision icon

Vision

To continue to contribute to the well-being of society and to improve people’s quality of life by marketing highly-innovative medicines and medical devices focusing particularly on wound healing, with products that fulfil the most stringent regulatory and quality requirements.

Values icon

Values

Our guiding values mirror our commitment to quality and innovation, providing effective solutions in complex wound-healing.

Values and principles such as trust, openness, integrity, honesty and professional respect are essential in the way we deal with our internal (employees and collaborators) and external (society, suppliers, distributors, clients and partners) clients.

Praxis has been engaged in the pharmaceutical industry for more than 10 years

Praxis Pharmaceutical currently operates in more than 15 countries with commercial branches in Spain (Madrid) and Colombia (Bogotá). From the outset, our expansion has been underpinned by close collaboration with our local and regional partners who specialise in their markets.
Timeline icon

2006

Praxis Pharmaceutical was founded, focusing on the treatment of diabetic foot ulcer and respiratory conditions.

^

2007

Praxis opened a new business unit specialising in cystic fibrosis in Spain and Portugal. Praxis was the only company to offer an integrated service in the treatment of this condition.

Timeline icon
Timeline icon

2009

It began to market products specialising in pulmonary hypertension in Spain and Portugal.

^

2012

An agreement is reached for the distribution of EPIPROT® (Recombinant Human Epidermal Growth Factor) in Colombia. With this milestone the internationalization of Praxis begins
Timeline icon
Timeline icon

2015

A commercial branch was opened in Colombia, tasked with the marketing of EPIPROT®. Praxis acquired the licence for manufacturing and marketing PolyHeal® Micro.
^

2016

Praxis transferred its respiratory business unit to focus on wound care.
Timeline icon
Timeline icon

2017

The CE marking was obtained for PolyHeal® Micro, an innovative medical device that reactivates the wound healing process through its unique Negatively-Charged Microspheres technology.
^

2018

The beginning of the international distribution of PolyHeal® Micro through commercial partners.
Timeline icon
Timeline icon

2019

The international expansion of PolyHeal® Micro through international partners and the launch of PolyHeal® Micro in Spain.
^

2020

The commercial branch in Colombia complemented its wound-healing portfolio by including Vulcosan® PHMB Antimicrobial complex, a sterile dressing indicated for the treatment of infected acute or chronic wounds.
Timeline icon
Timeline icon

2006

Praxis Pharmaceutical was founded, focusing on the treatment of diabetic foot ulcer and respiratory conditions.

Timeline icon

2007

Praxis opened a new business unit specialising in cystic fibrosis in Spain and Portugal. Praxis was the only company to offer an integrated service in the treatment of this condition.
Timeline icon

2009

It began to market products specialising in pulmonary hypertension in Spain and Portugal.
Timeline icon

2012

An agreement is reached for the distribution of EPIPROT® (Recombinant Human Epidermal Growth Factor) in Colombia. With this milestone the internationalization of Praxis begins
Timeline icon

2015

A commercial branch was opened in Colombia, tasked with the marketing of EPIPROT®. Praxis acquired the licence for manufacturing and marketing PolyHeal® Micro.
Timeline icon

2016

Praxis transferred its respiratory business unit to focus on wound care.
Timeline icon

2017

The CE marking was obtained for PolyHeal® Micro, an innovative medical device that reactivates the wound healing process through its unique Negatively-Charged Microspheres technology.
Timeline icon

2018

The beginning of the international distribution of PolyHeal® Micro through commercial partners.
Timeline icon

2019

The international expansion of PolyHeal® Micro through international partners and the launch of PolyHeal® Micro in Sapin.
Timeline icon

2020

The commercial branch in Colombia complemented its wound-healing portfolio by including Vulcosan® PHMB Antimicrobial complex, a sterile dressing indicated for the treatment of infected acute or chronic wounds.

R&D Projects

Our Research, Development and Innovation Projects were developed from the transversality, with teams included specialists from various technologies to offer integrated solutions. We developed our own projects and in collaboration projects together with companies and other research organisations.

  • Development of Sustainable processes.
  • New products for rare and poverty-related diseases.
  • Research and Development of new Active Pharmaceutical Ingredients.